Chargelegue D, Vine N D, van Dolleweerd C J, Drake P M, Ma J K
Guy's, King's and St. Thomas' School of Medicine and Dentistry, Department of Oral Medicine & Pathology, Guy's Hospital, London, UK.
Transgenic Res. 2000 Jun;9(3):187-94. doi: 10.1023/a:1008976219939.
Previous studies have shown that the production of recombinant antibodies in plants is highly efficient and presents numerous therapeutic applications. It is, however, known that plant glycoproteins display different glycosylation patterns to those exhibited by mammalian glycoproteins. Thus, it is important to know if these plant recombinant antibodies could induce undesirable immune responses in mammals; and to date no report has documented the potential immunogenicity of parenterally administered plant recombinant antibodies in animals. In order to answer this question, mice were immunised subcutaneously with a recombinant mouse monoclonal antibody produced in tobacco plants, together with alum as adjuvant. Two control groups were immunised in the same way with either the original murine monoclonal antibody or horseradish peroxidase (a plant glycoprotein). Analyses by direct immunoassay, competition immunoassay and real-time surface plasmon resonance, showed undetectable levels of antibody directed against both the protein and the glycan part of the plant recombinant antibody. These results have a direct relevance for the application of plant recombinant proteins as therapeutic agents and vaccines in humans.
先前的研究表明，在植物中生产重组抗体效率很高，且有众多治疗应用。然而，已知植物糖蛋白的糖基化模式与哺乳动物糖蛋白的不同。因此，了解这些植物重组抗体是否会在哺乳动物中诱导不良免疫反应很重要；迄今为止，尚无报告记录经肠胃外给药的植物重组抗体在动物中的潜在免疫原性。为了回答这个问题，用烟草植物中产生的重组小鼠单克隆抗体对小鼠进行皮下免疫，并以明矾作为佐剂。两个对照组以相同方式分别用原始鼠单克隆抗体或辣根过氧化物酶（一种植物糖蛋白）进行免疫。通过直接免疫测定、竞争免疫测定和实时表面等离子体共振分析表明，针对植物重组抗体的蛋白质和聚糖部分的抗体水平检测不到。这些结果对于植物重组蛋白作为人类治疗剂和疫苗的应用具有直接相关性。
